Abstract:
The patient was a 71-year-old woman with aquaporin-4-antibody positive neuromyelitis optica (NMO), with no history of diabetes. On admission, although she showed an extremely elevated plasma glucose level (1,080 mg/dL), her hemoglobin A1c level was low (7.1%), which indicated the rapid progression of diabetes. She also showed ketoacidosis and had a human leukocyte antigen haplotype, DRB1*09:01-DQB1*03:03 associated with Fulminant type 1 diabetes (FT1D). Based on these results, the patient was diagnosed with FT1D. We herein describe the first reported case of a patient with FT1D with NMO, which raises the possibility that T-cell-mediated autoimmunity is involved in the pathogenesis of both FT1D and NMO.

Key words: type 1 diabetes mellitus, neuromyelitis optica, diabetic ketoacidosis

(Intern Med 58: 1913-1916, 2019) 
(DOI: 10.2169/internalmedicine.2353-18)

Introduction

Fulminant type 1 diabetes (FT1D) is a subtype of ketosis-onset type 1 diabetes that is characterized by the extremely rapid progression of hyperglycemia and ketosis/ketoacidosis caused by the destruction of almost all pancreatic β cells. It has been established as a subtype of idiopathic type 1 diabetes mellitus (T1DM) (1, 2). Several reports indicate that genetic factors, such as human leukocyte antigen (HLA), and environmental factors, such as viral infections, contribute to the development of this disease (3, 4). Glycemic control is usually difficult to achieve in FT1D patients because their endogenous insulin is completely depleted; thus, we must pay special attention to the development of FT1D in the clinical setting (5).

Neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSDs) are inflammatory disorders of the central nervous system (CNS) characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting the optic nerves and spinal cord (6). The discovery of a disease-specific serum NMO-immunoglobulin G (IgG) antibody that selectively binds aquaporin-4 (AQP4) has increased the understanding of a diverse spectrum of disorders (7). NMO is still an incurable disease. The goals of treating acute NMO events are to improve relapse symptoms and restore neurological functions; long-term immunosuppression aims to prevent further attacks (6). FT1D is known to often accompany autoimmune diseases other than NMO (5). We herein report a case of FT1D that was observed during follow-up for NMO.

Case Report

A 71-year-old woman with NMO was referred to our department because of a 1-week history of vomiting and diarrhea. She also presented with overnight thirst. Although she continued to receive prednisolone (15 mg/day) for 1 year after the diagnosis of NMO, she had no history or evidence of diabetes mellitus. That is, her blood glucose levels had remained within a normal range until the last blood examination, which was carried out 3 months before her referral.

On physical examination, the patient’s blood pressure was 91/56 mmHg, her pulse was 100 beats/min, and her body...
temperature was 36.1°C. Her weight and height were 44.6 kg and 154 cm, respectively. She showed drowsiness, Kussmaul breathing, and no abdominal tenderness. Her mouth was dry, and her skin turgor was poor. The remaining findings of the neurological and general examinations were unremarkable. Her laboratory test data are shown in Table. The patient was treated with an intravenous fluid infusion and a continuous infusion of insulin. After these treatments, her physical condition and consciousness showed a rapid improvement. On the sixth hospital day, she was switched to multiple daily injections of insulin (Figure). Her diabetes has remained well controlled since then.

**Discussion**

We described the case of an elderly female patient with FT1D complicated by NMO. FT1D is characterized by rapid-onset diabetic ketoacidosis, low HbA1c, undetectable serum C-peptide, and negativity for islet-related autoantibodies (1); it is proposed as a novel subtype of idiopathic (type 1B) diabetes mellitus (8). Our clinical findings in this case were consistent with the diagnostic criteria for FT1D (9). In Japan, FT1D accounts for 0.2% of all new-onset diabetes cases, and 14.8-19.6% of acute-onset type 1 diabetes cases (10, 11). The most common symptoms are similar to those of the common cold, such as thirst (93.7%); abdominal symptoms such as nausea, vomiting, and abdominal pain (72.5%); flu-like symptoms (71.7%); and drowsiness (45.2%) (2). The pathogenesis of FT1D is influenced by genetic and environmental factors. Regarding genetic factors, HLA class II genes are strongly associated with susceptibility to progression to FT1D. The HLA DR4-DQ4 haplotype is common in Japanese individuals, but is rare in the Caucasian populations and might contribute to the different inci-

Table. The Laboratory Results of the Patient.

| Variable                          | Reference range | Variable                          | Reference range |
|----------------------------------|----------------|-----------------------------------|----------------|
| Complete blood count (On admission) |                | Arterial blood gas analysis (Room air, On admission) |                |
| White blood cell count (μL)      | 23,810         | pH                                | 7.08           |
| Red blood cells (x10^6/μL)       | 413            | pCO2                               | 13.5            |
| Hemoglobin (g/dL)                | 12.7           | pO2                                | 121.1           |
| Hematocrit (%)                   | 39.7           | Bicarbonate (mmol/L)               | 3.9             |
| Platelet count (x10^6/μL)        | 39             | Base excess (mmol/L)               | -24             |
| Biochemistry (On admission)      |                | Diabetes-related examination       |                |
| Total protein (g/dL)             | 6.4            | Glucose (mg/dL)                    | 1.054           |
| Albumin (g/dL)                   | 3.8            | HbA1c (3 months before admission)  | 6.4             |
| Blood urea nitrogen (mg/dL)      | 57.8           | HbA1c (On admission)               | 7.1             |
| Creatinine (mg/dL)               | 2.1            | 3-OHBA (μmol/L)                    | 10.114          |
| Amylase (U/L)                    | 1,319          | Acetoacetic acid (μmol/L)          | 3.972           |
| Lipase (U/L)                     | 73             | ΔCPR (6 min) during Glucagon stimulation |                |
| Elastase-1 (ng/dL)               | 3,773          |                                    |                |
| GOT (U/L)                        | 12             |                                    |                |
| GPT (U/L)                        | 23             |                                    |                |
| GGTP (U/L)                       | 72             |                                    |                |
| Na (mmol/L)                      | 132            | Serum CPR (1th day) (μg/dL)        | 0.37            |
| K (mmol/L)                       | 6.5            | Serum CPR (10th day) (μg/dL)       | 0.2             |
| Cl (mmol/L)                      | 97             | Urinary CPR (9th day) (μg/day)     | 3.7             |
| DNA typing                       |                |                                    |                |
| DRB1*09:01-DQB1*03:03            |                | Anti-GAD antibody negative         |                |
| DRB1*13:02-DQB1*06:04            |                | Anti-IA-2 antibody negative        |                |
| neureomylitis optica-related examination (On Diagnosis) | | Serological testing for virus |                |
| anti-aquaporin-4 antibody (U/mL) | 18.2           |                                    |                |
| CPR: C-peptide Immunoreactivity, GAD: Glutamic Acid Decarboxylase, IA-2: Insulinoma-associated Antigen-2, GPT: Glutamate Oxaloacetate Transaminase, 3-OHBA: 3-hydroxybutyric acid | | | |
Figure. The clinical course of insulin therapy. The upper panel shows the total insulin dose. The lower panel shows the mean glucose levels during the clinical course.

dences of FT1D between Japanese and Caucasian populations. Imagawa et al. reported that the frequency of HLA-DR4, but not -DR9, was significantly higher in FT1D, while the frequencies of HLA-DR1, -DR2, -DR5, and -DR8 were significantly lower. In contrast, DR9 but not DR4 was more frequent, and DR2 was extremely rare in T1DM (3). Additionally, a recent report indicated that the frequencies of the DRB1*04:05-DQB1*04:01 and DRB1*09:01-DQB1*03:03 haplotypes were significantly higher, and those of the DRB1*01:01-DQB1*05:01, DRB1:15:02-DQB1*06:01 and DRB1*08:03-DQB1*06:01 haplotypes were significantly lower in patients with FT1D than in the control subjects (4). Our patient also exhibited this typical HLA type. With regard to environmental factors, viral infections can trigger an accelerated immune reaction against infected β-cells, causing massive β-cell death and FT1D (12). In particular, enteroviral infection is related to the development of FT1D (3). In this case, we did not test for every viral infection, such as parainfluenza virus, enterovirus, Coxsackie virus, or human herpes virus 6 or 7. However, physicians should consider FT1D when viral infections are prevalent.

NMO is an autoimmune water channelopathy that predominantly affects astrocytes in the CNS, resulting in secondary demyelination, preferentially attacking the optic nerve, spinal cord, and circumventricular organs (6). It is recognized as an inflammatory demyelinating disease (IDD). After AQP4-IgG was discovered as the first serum biomarker of any IDD in 2004, it became accepted that the NMO entity is distinct from multiple sclerosis (13). Immunologic, epidemiologic, and pathologic evidence suggests that T cells play an important role in the etiology of NMO (14). Pathogenic AQP4-specific antibodies in NMO serum are predominantly IgG1, a T cell-dependent IgG subclass, and T cell-mediated CNS inflammation permits the entry of these antibodies into the CNS. In certain populations, NMO susceptibility is associated with allelic major histocompatibility complex II genes: in particular, HLA-DR17 (DRB1*0301). AQP4-specific T cells have been identified in patients, and T cells specific for dominant AQP4 epitopes exhibit Th17 polarization (7, 14).

Various autoimmune diseases have been reported in up to 30% of patients with NMO, suggesting that individuals with this condition might have a genetic predisposition to aberrant autoimmunity (14). However, a previous study demonstrated that none of 98 patients with NMO had diabetes, stiff-man syndrome, or epilepsy. All 98 patients tested positive for AQP4 antibodies. No patients tested positive for glutamic acid decarboxylase 65 or N-methyl-D-aspartate receptor antibodies (15). Although there is no direct common etiology indicated between FT1D and NMO, several lines of evidence have shown that these diseases might have a causal relationship. A previous report presented the case of a patient who developed type 1 diabetes mellitus and severe optic neuritis with AQP4 antibodies during treatment with combinations of drugs, including interferon (IFN)-α and IFN-γ for chronic hepatitis C (16). A more recent report described the first patient who developed anti-AQP4 antibody-positive NMO spectrum disorders as an anti-programmed cell death-1 (PD-1) antibody and nivolumab-induced immune-related adverse events (irAE) (17). PD-1 and programmed cell death-ligand-1 (PD-L1) inhibitors have been highlighted in the field of cancer treatment. The interaction between PD-1 and PD-L1 is thought to play an important role in the regulation of the self-immune tolerance mechanism, so blocking these molecules may cause serious irAEs, including FT1D (18). Hughes et al. described the develop-
ment of new-onset insulin-dependent diabetes in five patients after receiving anti-PD-1 antibodies, either as single agents or in combination with other cancer drugs (19). Several lines of evidence have indicated that regulatory T cells play a central role in suppressing the T cell-mediated immune response and the development of FT1D. Massive cellular infiltration of T cells and macrophages has been detected in islets and exocrine pancreas immediately after FT1D onset. Recently, it was reported that CD4+ CD45RA- Foxp3+-activated regulatory T cells - which play a central role in the T cell-mediated immune response - are functionally impaired in patients with FT1D (20). These findings suggested that both innate and acquired immune disorders might contribute to the development of FT1D. In this report, we pointed out the first patient with FT1D and NMO, raising the possibility that T cell-mediated autoimmunity is involved in the pathogenesis of both FT1D and NMO.

**Conclusion**

We reported the first case of FT1D complicated with NMO. FT1D is a life-threatening complication if treatment is delayed or the patient cannot be treated. Hence, careful consideration of the differential diagnosis is critical in patients with NMO who present with hyperglycemia. It is difficult to draw strong conclusions regarding the relationship between FT1D and NMO. This case report might raise the possibility that T cell-mediated autoimmunity is involved in the pathogenesis of both FT1D and NMO.

The authors state that they have no Conflict of Interest (COI).

**References**

1. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 342: 301-307, 2000.

2. Imagawa A, Hanafusa T, Uchigata Y, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26: 2345-2352, 2003.

3. Imagawa A, Hanafusa T, Uchigata Y, et al. Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia 48: 294-300, 2005.

4. Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T. Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Class II HLA genotype in fulminant type 1 diabetes; a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig 3: 62-69, 2012.

5. Liu L, Zeng L, Sang D, Lu Z, Shen J. Recent findings on fulminant type 1 diabetes. Diabetes Metab Res Rev 34: 1-7, 2018.

6. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85: 177-189, 2015.

7. Verkman AS, Anderson MO, Papadopoulos MC. Aquaporins: important but elusive drug targets. Nat Rev Drug Discov 13: 259-277, 2014.

8. Of D, Mellitus D. Diagnosis and classification of diabetes mellitus. Diabetes Care 37 (Suppl): 81-90, 2014.

9. Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 3: 36-45, 2007.

10. Imagawa A, Hanafusa T. Fulminant type 1 diabetes—an important subtype in East Asia. Diabetes Metab Res Rev 27: 959-964, 2011.

11. Takeda H, Kawasaki E, Shimizu I, et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 25: 995-1001, 2002.

12. Kotani R, Nagata M, Imagawa A, et al. T lymphocyte response against pancreatic beta cell antigens in fulminant Type 1 diabetes. Diabetologia 47: 1285-1291, 2004.

13. Lennon PVA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 364: 2106-2112, 2004.

14. Hardy TA, Reddell SW, Barnett MH, Palace J, Lucchinetti CF, Weinshenker BG. Atypical inflammatory demyelinating syndromes of the CNS. Lancet Neurol 15: 967-981, 2016.

15. Xie L, Long Y, Yang N, et al. No overlap among serum GAD65, NMDAR and AQP4 antibodies in patients with neuromyelitis optica spectrum disorders. Neuroimmunomodulation 22: 337-341, 2015.

16. Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 79: 773-783, 2016.

17. Narumi Y, Yoshiha R, Minami Y, et al. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. BMC Cancer 18: 95, 2018.

18. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens a systematic review and meta-analysis. JAMA Oncol 4: 173-178, 2018.

19. Hughes J, Vadattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 antibody immunotherapy. Diabetes Care 38: e55-e57, 2015.

20. Haseda F, Imagawa A, Murase-Mishiba Y, Terasaki J, Hanafusa T. CD4+CD45RA-FoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes. Clin Exp Immunol 173: 207-216, 2013.